Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Voraxaze Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Voraxaze (glucarpidase) Injection Coverage

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Part B coverage and prior authorization for provider-administered intravenous Voraxaze in adult and pediatric patients with toxic methotrexate concentrations and delayed clearance due to impaired renal function.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyVoraxaze (glucarpidase) Injection Coverage
    Policy CodePolicy N/A
    Change TypeCurrent policy
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming physician-administered IV injection, renal impairment, methotrexate concentration above 1 micromole/L, and required supportive therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50 units/kgMaximum single dose
    >1 micromole/LRequired methotrexate concentration
    ≤60 mL/minCreatinine clearance threshold
    Single doseDosing frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1,000 units
    Vial strength

    Coverage Criteria

    Methotrexate toxicity

    Covered when all of the following are met:

    Administration and clinical eligibility

    • Physician administration: Voraxaze is administered by a physician as an intravenous injection in an office or hospital outpatient department.

      The drug cannot be self-administered.

    • Delayed clearance due to renal impairment: The patient has delayed methotrexate clearance due to renal impairment.Creatinine clearance ≤60 mL/min
    • Toxic methotrexate concentration: The plasma methotrexate concentration is greater than one micromole per liter before the first dose of glucarpidase.>1 micromole/L before the first dose
    • Concurrent supportive therapy: Treatment is administered with IV hydration, urinary alkalinization, and leucovorin therapy.

      Leucovorin must not be administered within two hours before or after glucarpidase.

    Dose requirement

    Covered when at least one of the following dosing conditions is met:

    Dose requirements

    • Standard dose: The requested dose does not exceed 50 units/kg as a single dose.≤50 units/kg single dose
    • Supported off-label dose: The requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits the supporting evidence.

    Voraxaze is not recommended for patients who have expected methotrexate clearance and an expected plasma methotrexate concentration.

    Covered Codes and Clinical Coding Parameters

    NDC CodesNDCCovered
    50633-210-1110-digit NDC
    50633-0210-1111-digit NDC
    HCPCS CodesHCPCSCovered
    J3590Unclassified biologics
    CPT Procedural CodesCPTCovered
    96374Therapeutic/Prophylactic/Diagnostic injection, IV push
    96375Therapeutic/Prophylactic/Diagnostic IV injection, new drug add-on
    Pre-treatment plasma methotrexate concentration
    Required concentration>1 micromole per liter
    TimingBefore the first dose of glucarpidase
    Clinical useToxic plasma methotrexate concentration in adult and pediatric patients with delayed methotrexate clearance
    Creatinine clearance
    Creatinine clearance≤60 mL/min
    Associated conditionDelayed methotrexate clearance due to renal impairment

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Administration Setting

    Prior authorization is required for Voraxaze when requested for methotrexate toxicity. The drug must be administered as a physician-administered IV injection in an office or hospital outpatient department (HOPD), and coverage is subject to the clinical criteria below.

    • Administration must be by IV injection over five minutes.
    • Site of care: physician office or HOPD.
    Documentation Required

    Clinical Eligibility Documentation

    Document the clinical facts supporting eligibility, including delayed methotrexate clearance due to renal impairment and the pretreatment methotrexate concentration. The request should also identify the administration setting and confirm that the patient meets the applicable criteria.

    • Document delayed clearance due to renal impairment, defined as creatinine clearance of 60 mL/min or less.

    Voraxaze Background

    Voraxaze (glucarpidase) is a carboxypeptidase used to reduce toxic plasma methotrexate concentrations, including concentrations greater than 1 micromole per liter. It is indicated for adult and pediatric patients with delayed methotrexate clearance, particularly when delayed clearance is associated with impaired renal function. Delayed clearance is defined as plasma methotrexate concentrations greater than two standard deviations above the mean methotrexate excretion curve specific to the administered dose.

    Clinical Definitions and Monitoring

    Delayed methotrexate clearance
    StandardPlasma methotrexate concentrations greater than two standard deviations above the mean methotrexate excretion curve
    Dose specificityThe curve must be specific to the dose of methotrexate administered
    Condition describedDelayed methotrexate clearance
    Methotrexate concentration monitoring
    Measurement methodChromatographic method
    Monitoring windowWithin 48 hours following Voraxaze administration
    Immunoassay limitation

    Initial Therapy for Methotrexate Toxicity

    Initial therapy for methotrexate toxicity

    Initial treatment is covered when all of the following clinical, dosing, administration, and supportive-care criteria are met:

    Initial Voraxaze therapy

    • Physician administration and site of care: Voraxaze is administered by a physician as an intravenous injection in an office or hospital outpatient department.

      The drug cannot be self-administered.

    • Delayed clearance due to renal impairment: The patient has delayed methotrexate clearance due to renal impairment.Creatinine clearance ≤60 mL/min
    • Toxic methotrexate concentration: The plasma methotrexate concentration is greater than one micromole per liter before the first dose of glucarpidase.

    Dose and Quantity Limits

    Voraxaze (glucarpidase)
    Maximum dose50 units/kg
    AdministrationSingle IV injection over five minutes
    Approved quantityApproved per needed single dose
    Vial strength1,000 units as a lyophilized powder for reconstitution

    Administration Setting

    Billing Rule

    Office administration required

    In the office setting, Voraxaze must be administered by a physician as an intravenous injection. It cannot be self-administered.

    • Use physician-administered IV injection.
    • Administration is permitted in an office or hospital outpatient department.
    Billing Rule

    Hospital outpatient administration required

    In a hospital outpatient department, Voraxaze must be administered by a physician as an intravenous injection. It cannot be self-administered.

    • Use physician-administered IV injection.
    • Administration is permitted in a hospital outpatient department or office.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyVoraxaze (glucarpidase) Injection Coverage
    Policy CodePolicy N/A
    Change TypeCurrent policy
    Effective DateFeb 12, 2026
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming physician-administered IV injection, renal impairment, methotrexate concentration above 1 micromole/L, and required supportive therapy.
    SourceLink
    On This Page
    Coverage CriteriaCovered Codes and Clinical Coding ParametersAuthorization, Documentation, and Denial RisksVoraxaze BackgroundClinical Definitions and MonitoringInitial Therapy for Methotrexate ToxicityDose and Quantity LimitsAdministration Setting
    Coverage requirement
    The patient must have delayed methotrexate clearance due to renal impairment with creatinine clearance of 60 mL/min or less
    Delayed methotrexate clearance definition
    DefinitionPlasma methotrexate concentration greater than two standard deviations above the mean methotrexate excretion curve
    Curve basisThe mean methotrexate excretion curve specific to the administered methotrexate dose
    Clinical contextDelayed methotrexate clearance associated with toxic plasma methotrexate concentration
  1. Provide the plasma methotrexate concentration before the first glucarpidase dose; it must be greater than 1 micromole/L.
  2. Identify that administration will occur in a physician office or HOPD.
  3. Confirm the request is not for self-administration or a second dose.
  4. Documentation Required

    Required Supportive Therapy

    Voraxaze must be administered with IV hydration, urinary alkalinization, and leucovorin therapy. Leucovorin must be given at least two hours before or two hours after glucarpidase; for the first 48 hours after Voraxaze, use the same leucovorin dose given before treatment.

    • Document IV hydration and urinary alkalinization.
    • Document concurrent leucovorin therapy.
    • Do not administer leucovorin within two hours before or after glucarpidase.
    • After 48 hours, continue leucovorin based on measured methotrexate concentration until it remains below the treatment threshold for at least three days.

    Unsupported block type: documentation

    Documentation Required

    Post-Treatment Methotrexate Monitoring

    Measure methotrexate concentrations within 48 hours after Voraxaze administration using a chromatographic method. Immunoassays are unreliable for samples collected during this period.

    • Obtain methotrexate concentrations within 48 hours after administration.
    • Use a chromatographic method; do not rely on immunoassay results during this window.
    Denial Risk

    Expected Clearance Is Not Covered

    Coverage may be denied when the patient has the expected methotrexate clearance and expected plasma methotrexate concentration, because Voraxaze is not recommended in that circumstance.

    • Covered use requires delayed clearance and a toxic plasma methotrexate concentration.
    • The labeled toxic concentration is greater than 1 micromole/L.
    Denial Risk

    Clinical Criteria Not Met

    Coverage may be denied when the clinical eligibility criteria are not met. This includes delayed clearance that is not due to renal impairment, creatinine clearance above 60 mL/min, a pretreatment methotrexate concentration of 1 micromole/L or less, or failure to provide required supportive therapy or dose support.

    • Delayed clearance must be due to renal impairment.
    • Creatinine clearance must be 60 mL/min or less; values above 60 mL/min do not meet the criterion.
    • Pretreatment plasma methotrexate concentration must be greater than 1 micromole/L.
    • IV hydration, urinary alkalinization, and appropriately timed leucovorin therapy are required.
    • For doses above 50 units/kg, submit supporting guidelines or peer-reviewed literature.
    Denial Risk

    Second Dose May Be Denied

    A second glucarpidase dose may be denied because patients who received a second dose failed to achieve efficacy. Requests should therefore be limited to the eligible single-dose treatment unless additional coverage criteria are established.

    • The approval criteria specify a single dose.
    • A second dose lacks demonstrated efficacy in the policy criteria.
    Denial Risk

    Dose Exceeds Single-Dose Limit

    A request exceeding 50 units/kg may be denied unless the prescriber submits practice guidelines or peer-reviewed literature supporting the requested dose for the relevant off-label use.

    • Standard single-dose limit: 50 units/kg.
    • Supporting evidence is required for any higher dose.
    Denial Risk

    Self-Administration Not Covered

    Voraxaze must be administered intravenously by a physician in an office or HOPD. Coverage may be denied when the patient or caregiver is expected to self-administer the drug.

    • Physician-administered IV injection only.
    • Self-administration is not permitted.
    Immunoassays are unreliable for samples collected within 48 hours following Voraxaze administration
    >1 micromole/L before the first dose

    Patients who received a second dose failed to achieve efficacy.

  5. Supportive therapy: Treatment includes IV hydration, urinary alkalinization, and leucovorin therapy.

    Leucovorin must not be administered within two hours before or after glucarpidase.

  6. Dose requirement

    • Standard dose: The requested dose does not exceed 50 units/kg as a single dose.≤50 units/kg single dose
    • Supported off-label dose: The requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits the supporting evidence.